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ABSTRACT
Hyaluronan, the main glycosaminoglycan of extracellular matrices, is concentrated 
in tissues with high cell proliferation and migration rates. In cancer, hyaluronan 
expression is altered and it becomes fragmented into low-molecular-weight forms, 
affecting mechanisms associated with cell proliferation, invasion, angiogenesis and 
multidrug resistance. Here, we analyzed the effect of low-molecular-weight hyaluronan 
on the response of T lymphoma, osteosarcoma, and mammary adenocarcinoma cell 
lines to the antineoplastic drug doxorubicin, and whether co-treatment with hyaluronan 
and doxorubicin modified the behavior of endothelial cells. Our aim was to associate 
the hyaluronan-doxorubicin response with angiogenic alterations in these tumors. 
After hyaluronan and doxorubicin co-treatment, hyaluronan altered drug accumulation 
and modulated the expression of ATP-binding cassette transporters in T-cell lymphoma 
cells. In contrast, no changes in drug accumulation were observed in cells from solid 
tumors, indicating that hyaluronan might not affect drug efflux. However, when we 
evaluated the effect on angiogenic mechanisms, the supernatant from tumor cells 
treated with doxorubicin exhibited a pro-angiogenic effect on endothelial cells. 
Hyaluronan-doxorubicin co-treatment increased migration and vessel formation in 
endothelial cells. This effect was independent of vascular endothelial growth factor 
but related to fibroblast growth factor-2 expression. Besides, we observed a pro-
angiogenic effect on endothelial cells during hyaluronan and doxorubicin co-treatment 
in the in vivo murine model of T-cell lymphoma. Our results demonstrate for the first 
time that hyaluronan is a potential modulator of doxorubicin response by mechanisms 
that involve not only drug efflux but also angiogenic processes, providing an adverse 
tumor stroma during chemotherapy.
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INTRODUCTION
Hyaluronan (HA), a large linear polysaccharide, 
is the main glycosaminoglycan found in all types of 
mammalian extracellular matrices (ECM). HA is able 
to interact with cell surface receptors such as CD44 and 
RHAMM, activating different cellular signals [1, 2]. It 
is well known that, in malignant tumors, HA expression 
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is altered in comparison to normal tissues [3]. In fact, 
during cancer transformation, HA is fragmented into 
low-molecular-weight (LMW) forms, which have been 
shown to promote cell proliferation, adhesion and motility, 
and are considered tumor growth promoters [4]. High 
expression of CD44, the main HA receptor, is associated 
with a normal and tumor stem cell-like phenotype [5]. 
In this sense, tumor stem cells currently exhibit high 
resistance to chemotherapeutic agents, since they also 
present an increased expression of different multidrug 
resistance ATP-binding cassette (ABC) transporters, 
such as ABCB1 (P-glycoprotein), ABCC1, and ABCG2, 
which modulate cytotoxic drug efflux [6–8]. Some works 
have shown that the CD44-HA interaction affects the 
function of drug transporters by several mechanisms, 
including the modulation of their gene expression and 
activity [9]. Opposite to the action of native HA, it 
has been demonstrated that HA fragments sensitize 
vincristine-resistant lymphoma cell lines by modulating 
P-glycoprotein activity and the PI3K/Akt survival pathway 
[10–12].
HA is also an important factor involved in tumor 
angiogenesis. This molecule promotes the formation of 
tumor-associated vasculature by inducing the expression 
of different angiogenic factors such as vascular endothelial 
growth factor (VEGF) and the fibroblast growth factor 
(FGF). These processes activate a continuous angiogenesis 
and different oncogenic pathways, inhibition of apoptosis 
and acquisition of a tumor stem cell-like phenotype [13]. 
Moreover, it has been observed that, during treatment 
with the antineoplastic drug doxorubicin (DOX), tumor-
associated endothelial cells (ECs) acquire resistance to the 
antiangiogenic drug sunitinib [14]. 
Regarding the oncogenic pathway, the canonical 
Wnt/β-catenin and PI3K/Akt signaling pathways have 
been linked with many types of cancers. It has been 
documented that Wnt signaling regulates CD44 expression 
and function, and reciprocally CD44 targets the Wnt 
pathway [15–17]. Aberrant activation of the PI3K/Akt 
signaling pathway leads to tumor cell survival, and several 
studies have demonstrated that the HA-CD44 interaction 
sustains the activation of phosphorylated Akt (p-Akt) 
signaling and modulates tumor progression [12]. These 
pathways result in an interesting potential therapeutic 
target to inhibit metastasis, drug resistance and recurrence 
processes [18–21].
Tumor-associated ECs may develop drug resistance 
through the regulation of different cellular pathways; in 
this way, they also need to be eliminated by chemotherapy 
treatment to minimize tumor progression and risk of 
recurrence [8]. 
In the present work, we studied the effect of HA 
on DOX treatment in different tumor cell lines and 
evaluated the modulation of DOX accumulation as well 
as the activation of Wnt and PI3K/Akt pathways. We 
also analyzed the impact of these treatments on ECs 
behavior. Our data indicate that the presence of LMW HA 
in tumor stroma could negatively influence the response 
to chemotherapy treatment, in part by inducing β-catenin 
expression and p-Akt in tumor and associated stromal 
cells. Importantly, we observed functional alterations in 
ECs, which affected the angiogenic response and thus 
affect the success or failure of the tumor treatment.
RESULTS
CD44 expression and HA binding in tumor cells
To study whether EL4 (murine T-cell lymphoma) 
and K12 (murine osteosarcoma) cell lines were able 
to respond to HA treatment, we first analyzed CD44 
expression and HA binding ability in these tumor cell lines. 
Regarding CD44 expression, EL4 cells showed 
two cell populations with different mean fluorescence 
intensity (MFI) of CD44: one main population with high 
CD44 expression (MFI: 641) and a small population with 
lower CD44 expression (MFI: 219) (Figure 1A), whereas 
regarding HA binding ability, EL4 cells presented three 
populations which bound HA with different MFI levels 
(HAhigh: 14300, HAmid: 2144, HAlow: 460) (Figure 1B). 
Similarly, the K12 osteosarcoma cell line showed 
two populations with different CD44 expression levels 
(CD44high: 12500 and CD44mid: 1347) (Figure 1C), which 
bound HA with different MFI levels (HAmid 2144, HAhigh: 
6941) (Figure 1D). 
As it is known, the MDA-MB-231 cell line is used 
as a model of invasive breast cancer, expressing high 
levels of CD44 and binding HA efficiently [22]. Thus, we 
also studied this cell line and found high CD44 and HA 
binding levels by flow cytometry (data not shown). 
Effect of LMW HA-DOX co-treatment on 
drug accumulation, expression of ABC drug 
transporters and cell death
To analyze the effect of HA as a modulator of 
drug response in tumor cells, we used DOX because it 
is used to treat a broad spectrum of solid tumors (breast 
adenocarcinoma, osteosarcoma, bronchogenic carcinoma, 
and neuroblastoma) as well as hematologic malignancies 
(lymphomas and acute leukemia) [23]. Previous works 
have shown the ability of ECM components, such as HA, 
to modulate drug resistance [24, 25]. Considering these 
previous data, we decided to evaluate the potential effect of 
exogenous HA (mimicking the tumor microenvironment) 
on DOX accumulation and apoptosis induction in the three 
tumor cell lines mentioned above. 
Different doses of DOX (0.5 µM; 1 µM; and 2.5 µM) 
in combination with LMW HA (20 µg/ml and 100 µg/ml) 
were used to evaluate DOX accumulation by flow 
cytometry analysis. DOX doses were selected considering 
values below the IC50 for each cell line (Supplementary 
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Figure 1: IC50EL4: 2.4 µM; IC50K12: 6.8 µM; IC50MDA-MB-231: 
4.9 µM) to avoid effects of high levels of cell death. The 
presence of functional drug efflux pumps was confirmed by 
using the specific ABC transporter inhibitor Cyclosporine 
A (CsA) in the three cell lines (data not shown).
A significant reduction of DOX intracellular levels 
was observed in EL4 cells only when 1 μM DOX was 
combined with 100 µg/ml LMW HA, whereas no changes 
in DOX accumulation were observed in K12 or MDA-
MB-231 cells (Figure 2A). In agreement, no significant 
differences in DOX-induced apoptosis were found after 
DOX and HA co-treatment in all cell lines (Figure 2B). 
Since we observed differences in DOX accumulation 
after LMW HA-DOX co-treatment only in EL4 cells, 
we analyzed the expression of ABC transporter genes 
involved in DOX efflux (ABCB1 and ABCG2) only in this 
cell line. No changes in the expression of ABCG2 mRNA 
were found during co-treatment with LMW HA and DOX 
(data not shown). Nevertheless, when EL4 cells were 
treated with 1 µM DOX, the addition of 20 µg/ml of LMW 
Figure 1: Flow cytometry analysis of CD44 expression and hyaluronan (HA) binding ability in EL4 (A and B) and K12 (C and D) cell 
lines. Graphs show the Mean Fluorescence Intensity (MFI) of cell populations with different CD44 expression level and HA binding ability, 
representative of three independent experiments.  
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HA (1.879 ± 0.783) or 100 µg/ml of LMW HA (2.163 
± 0.705) increased ABCB1 mRNA expression respect to 
DOX alone (Figure 3A). These data are in concordance 
with the reduction of intracellular accumulation of DOX 
observed in EL4 in this condition. 
EL4 cells were confirmed to have functional pumps 
since, during the treatment with CsA, DOX accumulation 
was evidently reduced (Figure 3B). These results indicate 
that LMW HA may not play a role as a modulator of DOX 
accumulation and apoptosis in cell lines derived from 
these solid tumors. However, HA might affect intracellular 
DOX increase by inducing ABCB1 mRNA expression in 
hematopoietic malignancies. 
Evaluation of β-catenin and p-Akt expression 
after LMW HA-DOX co-treatment 
Since the modulation of different pathways 
involved in cell survival and proliferation contributes to 
carcinogenesis and affects drug response, we analyzed 
β-catenin and p-Akt expression after the combination of 
treatments with LMW HA (20 and 100 µg/ml) and DOX 
(0.5, 1 and 2.5 µM).
In the EL4 cell line treated with different 
concentrations of LMW HA, β-catenin expression increased, 
with a significant difference at 20 µg/ml with respect to 
basal conditions. In turn, DOX treatment increased β-catenin 
protein levels, standing out at the co-treatment with 1 μM 
DOX and 100 µg/ml of LMW HA (*p < 0.05) (Figure 4A). 
Regarding K12 cells, LMW HA treatment did 
not affect β-catenin expression, but co-treatment with 
0.5 µM DOX and 100 µg/ml of LMW HA increased 
protein expression respect to 0.5 µM DOX (**p < 0.01). 
Treatment with 1 µM DOX also enhanced protein 
expression, but the addition of LMW HA showed no 
significant changes (Figure 4A). 
Finally, both LMW HA doses significantly increased 
β-catenin in MDA-MB-231 cells with respect to basal 
conditions (BC) (*p < 0.05) (Figure 4A). Moreover, when 
cells were treated with 0.5 µM DOX and 20 µg/ml of 
LMW HA, β-catenin levels were significantly higher (*p < 
0.05) (Figure 4A). The original nitrocellulose membranes 
from the three independent experiments for β-Catenin and 
GAPDH blots are shown in the Supplementary Figure 2. 
Taken together, these results indicate that LMW HA-DOX 
co-treatment modulates β-catenin expression in the tumor 
cell lines studied. 
As known, HA stimulation induces PI3K/Akt pathway 
activation by specific phosphorylation in several tumor cell 
lines. Thus, and because this activation plays an important 
role in cancer response to anti-tumoral drugs [26], we 
decided to evaluate p-Akt expression in the three cell lines.
In EL4 cells, the treatment with 100 µg/ml of LMW 
HA significantly increased the expression of p-Akt vs. BC 
(*p < 0.05), whereas the treatment with DOX (0.5 µM and 
1 µM) induced no differences in p-Akt levels (Figure 4B). 
When 0.5 µM DOX was combined with 20 or 100 µg/ml 
of LMW HA, p-Akt levels increased significantly in 
Figure 2: Effect of LMW HA on drug accumulation and cell death. Flow cytometry analysis of doxorubicin (DOX) accumulation 
(A) and apoptosis (B) evaluated in EL4, K12 and MDA-MB-231 cell lines. Cells were incubated with 0.5, 1 and 2.5 µM of DOX alone (0.5 D, 
1 D and 2.5 D) or plus 20 or 100 µg/ml of LMW HA (L20 and L100 respectively). To measure apoptosis levels, cells were labeled with 
AnnexinV-FITC and analyzed by flow cytometry. Values are expressed as arithmetic means ± standard deviation (SD) evaluated in three 
independent experiments. *p < 0.05, **p < 0.01 vs. untreated cells. 
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comparison with 0.5 DOX alone (**p < 0.01 and **p < 0.01 
respectively). We found similar results with 1 µM DOX 
in combination with both concentrations of LMW HA. 
However, no statistically significant differences were 
found (Figure 4B). These results indicate that LMW HA 
is capable of reversing the anti-tumoral action of DOX. 
In the K12 cell line, we found no detectable levels of 
p-Akt in the western blot assay under these experimental 
conditions.
Finally, when we analyzed p-Akt expression in MDA-
MB-231 cells, we found an increase in p-Akt expression 
when cells were treated with 20 and 100 μg/ml of LMW HA 
(Figure 4B). The original nitrocellulose membranes from 
the three independent experiments for  p-Akt and GAPDH 
blots are shown in the Supplementary Figure 3. These results 
suggest that HA treatment favors tumor progression by 
activating the signaling pathways involved in tumor survival, 
as was expected. Nevertheless, we observed no differences 
in p-Akt levels during HA-DOX co-treatment (Figure 4B).
Modulation of endothelial cell behavior in 
response to LMW HA-DOX co-treatment
As known, DOX treatment is efficient in inducing 
tumor cell death. However, in tumor and stromal cells, the 
tumor microenvironment and its ECM components can 
impair and modulate these responses, by modulating ECs 
and thereby angiogenesis [27]. To evaluate whether LMW 
HA was able to affect the angiogenic response of tumor 
cells, supernatants from each treatment (LMW HA alone 
or plus DOX) were collected and stored as described in 
the materials and methods section. Subsequently, these 
supernatants were used to perform wound healing and 
tube formation assays on ECs, as well as to evaluate the 
expression of soluble pro-angiogenic factors. Controls 
to discard DOX or HA residual effects on ECs were also 
performed during each experiment.
Supernatants from EL4 cells treated with 20 µg/ml 
of LMW HA induced a significant increase in the 
migration of ECs vs. BC since a reduction of the scratch 
area was observed (*p < 0.05) (Figure 5A). When ECs 
were stimulated with supernatants from DOX treatments, 
migration levels were similar to BC, suggesting that DOX 
itself does not stimulate an angiogenic response in EL4 
cells (Figure 5A). However, 100 µg/ml of LWM HA in 
combination with 1 µM DOX diminished ECs migration 
compared with HA treatment (*p < 0.05) (Figure 5A).
To confirm these results, we performed a tube 
formation assay stimulating ECs in the same conditions 
as for the wound healing assay. LMW HA treatment 
(at both 20 µg/ml and 100 µg/ml) appeared to have a 
pro-angiogenic effect (1.397 ± 0.175 and 1.394 ± 0.06 
respectively). Nevertheless, the data were not statistically 
significant (Figure 6A). Treatment with DOX and its 
combination with LMW HA did not show an increase in 
ECs tube formation, indicating that it does not affect the 
angiogenic behavior of ECs in vitro (Figure 6A).
When ECs migration was studied using K12 cell 
supernatants from LMW HA treatments, as expected, 
we observed a pro-angiogenic effect. During the wound 
healing assay, an increase in ECs migration was found 
when the cells were stimulated with the supernatant of 
the treatment with 100 µg/ml of LMW HA (**p < 0.01) 
(Figure 5B). In addition, when the tube formation assay 
was performed, the supernatant of the treatment with 
100 µg/ml of LMW HA significantly stimulated ECs tube 
formation, increasing the number of vessel-like structures 
respect to BC (1.43 ± 0.05 vs. 1.156 ± 0.03 ***p < 0.001) 
(Figure 6B). DOX treatment itself had a pro-angiogenic 
action on these tumor cells, since supernatants from 
the treatments with 0.5 µM and 1 µM DOX induced 
higher levels of both EC migration (Figure 5B) and tube 
formation (1.30 ± 0.03 ***p < 0.001 and 1.324 ± 0.01 
**p < 0.01 respectively vs. BC: 1.156 ± 0.03) (Figure 6B). 
Figure 3: Expression and function of drug efflux pumps in response to LMW HA and DOX co-treatment. ABCB1 
mRNA quantification by RT-qPCR in EL4 cells after DOX and HA co-treatment. GAPDH mRNA expression was used as reference gene 
(A). The function of drug efflux pumps in EL4 cells was evaluated studying DOX accumulation in the presence of 100 µM of the blocking 
agent Cyclosporine A (CsA) (B). Results are expressed as means ± SD obtained in three independent experiments. *p < 0.05, **p < 0.01 
vs. untreated cells.
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Besides, we found significant differences when ECs were 
stimulated by DOX plus LMW HA supernatants in the 
wound healing assay. Supernatants from the treatment 
with 5 µM DOX plus 20 µg/ml of LMW HA significantly 
stimulated EC migration (*p < 0.05) (Figure 5B), as well 
as tube formation (0.5 µM DOX: 1.30 ± 0.03 vs. 0.5 µM 
DOX + 20 µg/ml LMW HA: 1.76 ± 0.02 and 0.5 µM DOX 
+ 100 µg/ml LMW HA: 2.536 ± 0.01 ***p < 0.001) (1 µM 
DOX: 1.324 ± 0.01 vs. 1 µM DOX+ 20 µg/ml LMW HA: 
2.008 ± 0.01 and 1 µM DOX + 100 µg/ml LMW HA: 
1.477 ± 0.05 **p < 0.01) (Figure 6B).
Finally, when ECs were treated with HA 
supernatants from MDA-MB-231 cells, both doses of 
LMW HA significantly enhanced ECs migration in the 
wound healing assay (***p < 0.001) (Figure 5C). When 
we used supernatants of these cells treated with DOX, the 
three doses (0.5, 1 and 2.5 µM) induced an increase in 
ECs migration compared to BC. Nevertheless, statistically 
significant differences were found only with 0.5 µM DOX 
combined with 100 µg/ml LMW HA with respect to BC 
(*p < 0.05) (Figure 5C). 
In concordance with the results obtained in the 
wound healing assay, LMW HA treatment induced a 
higher formation of tube-like structures in ECs (20 µg/ml 
of LMW HA: 7.879 ± 0.23 ***p < 0.001; 100 µg/ml of 
LMW HA: 7.226 ± 0.71 *p < 0.05) in comparison with 
supernatants of untreated MDA-MB-231 cells (BC: 
5.928 ± 0.56) (Figure 6C). When ECs were exposed to 
supernatants from 0.5 DOX plus both LMW HA doses 
(0.5 µM DOX + 20 µg/ml LMW HA: 6.587 ± 0.37 
*p < 0.05 and 0.5 µM DOX + 100 µg/ml LMW HA: 
7.108 ± 0.38 ***p < 0.001), we found an increase in 
tube formation in comparison with DOX alone (0.5 µM 
DOX: 5.535 ± 0.29) (Figure 6C), corresponding with the 
results obtained in the wound healing assays. Controls to 
discard residual effects of DOX or HA on ECs were also 
performed during in vitro assays, and results were similar 
to those for BC (data not shown). 
Figure 4: Modulation of β-Catenin and p-Akt expression by DOX and HA co-treatment. Protein expression of β-Catenin 
(A) and p-Akt (B) was evaluated in EL4, K12 and MDA-MB-231 cells by western blot. Protein extracts were prepared from untreated 
cells (basal control: BC) or cells treated with HA, DOX, and DOX with HA co-treatment. GAPDH expression was used as loading control. 
Densitometry analysis of western blot bands was performed, and results are expressed as means ± SD of arbitrary units obtained in three 
independent experiments. *p < 0.05, **p < 0.01 vs. untreated cells. 
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Figure 5: Modulation of endothelial cell migration in response to LMW HA and DOX co-treatment. HMEC-1 cells were 
stimulated with EL4 (A), K12 (B) or MDA-MB-231 (C) supernatants for 24 h. Graphs show the scratch area measured every 4 h. Pictures 
show the most representative experiment out of three performed. Values are expressed as the arithmetic mean ± SD of three independent 
experiments. *p < 0.05, **p < 0.01 vs. untreated cells.
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As EL4 cells showed no angiogenic effect compared 
with K12 and MDA-MB-231 cells in the in vitro assays, 
we decided to evaluate the effect of DOX and HA co-
treatment on tumor angiogenesis in an in vivo model of 
murine T-cell lymphoma. 
Once the s.c. tumor was established, treatments with 
LMW HA (20 µg/ml and 100 µg/ml), DOX (1 µM), or 
the combination of both treatments were performed for 
48 h. After that time, mice were sacrificed. Subsequently, 
fluorescent lectin-specific staining was used to determine 
the presence of ECs and vessels in the tumor tissue. 
We observed an increase in ECs label (20 µg/ml: 
2.254 ± 0.88 and 100 µg/ml:3.057 ± 0.58) and vessel-like 
structures during the treatment with both doses of LMW 
Figure 6: Endothelial cell tube formation assay. HMEC-1 cells seeded on a Geltrex™ support were stimulated with EL4 (A), 
K12 (B) or MDA-MB-231 (C) supernatants. Graphs show the quantification of the arithmetic means ± SD of EC tube formation of three 
independent experiments. Representative micrographs show the formation of the endothelial network after 6 h of seeding on a Geltrex™ 
support and stimuli with tumor cells supernatants. C−: DMEM; C+: ECs stimulated with 100 ng/ml of VEGF; BC: supernatant of untreated 
tumor cells. *p < 0.05 *** p < 0.001 vs. untreated cells. 
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Figure 7: In vivo angiogenesis in a model of T-cell lymphoma l. Micrographs show the expression of GSL-1-FITC by fluorescence 
microscope in tumor sections of the EL4 T-cell lymphoma model. C57BL/6 mice were inoculated with EL4 cells and, on day 7, tumors 
were inoculated s.c. with saline, LMW HA, DOX or DOX plus LMW HA. Tumors were fixed and stained with GSL1-FICT (green, 
endothelial cells) and DAPI (blue, nuclei) (A). Tumors were fixed and stained with hematoxylin/eosin (B). Bars represent means of GSL-
1-FITC+/field ± SD from ten representative visual fields obtained in three independent experiments (C). ***p < 0.001 vs. untreated tumors. 
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HA respect to the tumor tissues from mice that did not 
receive treatment (1.181 ± 0.05; ***p < 0.001) (Figure 7). 
Contrary to the results obtained in vitro, when 1 µM DOX 
was combined with 20 or 100 µg/ml of LMW HA, an 
increase in ECs and vessels label was observed (2.412 ± 
0.33 and 2.50 ± 0.32 respectively) (Figure 7) comparing 
to tumor tissues from mice treated with 1 µM DOX alone 
(1.041 ± 0.17; ***p < 0.001). These results could indicate 
that although angiogenic modulation was not observed in 
vitro, LMW HA disturbs DOX action, up-regulating the 
angiogenesis process during this therapy.
Expression of pro-angiogenic factors after LMW 
HA-DOX co-treatment
Since VEGF is one of the most important factors 
involved in angiogenesis [28–30], we next analyzed 
whether VEGF could be one of the soluble factors 
involved in the modulation of angiogenesis under HA 
and DOX co-treatment. To this end, we evaluated VEGF 
secretion in tumor cell supernatants after DOX and LMW 
HA treatments. When VEGF concentration was measured 
in EL4 cells (Figure 8A), no significant differences 
were observed between treatments. In contrast, and 
unexpectedly, when VEGF expression was evaluated in 
K12 cells, a significant reduction of VEGF levels was 
observed in all treatments, compared to BC (Figure 8A). 
When VEGF levels were measured in MDA-MB-231 
supernatants, no difference in protein concentration was 
observed (Figure 8A). 
Considering that no differences in VEGF 
expression were detected in supernatants of tumor cells, 
other factors could be involved in tumor angiogenesis 
and be related to aggressive phenotypes of different 
types of cancer cells [31–33]. Since, FGF-2 is a potent 
cell survival factor involved in tumor angiogenesis 
[33–35] we decided to evaluate FGF-2 expression in 
EL4, K12, and MDA-MB-231 cells. First, we analyzed 
FGF-2 protein expression by using supernatants from 
the three cell lines after performing all treatments with 
LMW HA and DOX. However, no detectable levels 
were found by ELISA. Because FGF-2 is not frequently 
detected into the medium of cultured cells because 
remains associated with cell-surface heparan sulfate 
proteoglycans (HSPGs) upon secretion [36–38], we 
performed the ELISA with total cellular protein extracts 
from each cell line.
When we evaluated the biosynthesis of FGF-2 
in EL4 cells, treatment with 20 µg/ml of LMW HA increased 
FGF-2 expression levels, although no significant differences 
were found. When 0.5 µM DOX was combined with 
100 µg/ml of LMW HA, an increase in FGF-2 levels was 
observed compared with 0.5 µM DOX alone (p = 0.055). 
In addition, the treatment with 1 µM DOX and 20 µg/ml 
of LMW HA also showed higher levels of FGF-2 than the 
treatment with 1 µM DOX alone (not significant) (Figure 8B).
Figure 8: Analysis of pro-angiogenic factors expression after LMW HA and DOX co-treatment. A VEGF (A) and FGF-2 
(B) concentration levels (pg/ml) were detected in EL4, K12 and MDA-MB-231 supernatants by ELISA. Results are expressed as means ± 
SD obtained in three independent experiments. *p < 0.05, **p < 0.01 vs. untreated cells.
Oncotarget36595www.oncotarget.com
Conversely, no changes in FGF-2 expression were 
observed when K12 cells were treated with LMW HA 
(Figure 8B). When 1 µM DOX was combined with 20 µg/ml 
of LMW HA, FGF-2 levels increased with respect to 
treatment with 1 µM DOX alone (Figure 8B). 
Since the highest pro-angiogenic effect was 
observed in MDA-MB-231 cells, we decided to evaluate 
both mRNA and protein levels of FGF-2 after LMW HA 
and DOX treatments. The treatment with 20 µg/ml of 
LMW HA induced a significant increase in FGF-2 mRNA 
levels (Figure 8B). Furthermore, the LMW HA plus 
DOX treatment induced a higher expression of FGF-2 
than DOX treatment alone (Figure 8B). When we studied 
the biosynthesis of FGF-2 by ELISA, the treatment with 
20 µg/ml of LMW HA increasedFGF-2 levels. In 
agreement with our previous results, DOX treatment per 
se showed no pro-angiogenic action. However, when 
0.5 µM DOX was combined with 100 µg/ml of LMW HA, 
FGF-2 expression increased significantly in comparison with 
0.5 µM DOX alone (*p < 0.05) (Figure 8B). These results 
can explain the pro-angiogenic effect on ECs detected in all 
in vitro assays using MDA-MB-231 cells (Figures 5 and 6). 
Our results demonstrate for the first time that HA 
is a potential modulator of the angiogenic response in 
combination with DOX treatment. The effect of adding 
HA to DOX treatment is related to the modulation of 
the expression of pro-angiogenic factors, which finally 
increase EC migration. Besides, we also showed that 
a chemotherapeutic drug such as DOX could affect 
tumor angiogenesis by modulating the expression of the 
angiogenic factor FGF-2. 
DISCUSSION 
In cancer, one of the main causes of recurrence and 
mortality is the development of drug resistance. The tumor 
microenvironment is formed by different populations of 
cells (cancer and stromal cells) and ECM components, 
whose interactions influence the sensitivity to apoptosis 
and affect drug response, potentially inducing the 
appearance of resistance to chemotherapy [39].
In the present study, our objective was to elucidate 
whether the interaction of HA with tumor cells from 
different histological origin affects the response to the 
antineoplastic drug DOX and in turn the angiogenesis 
process, determining a general or differential action of HA 
within these tumors. To this end, we used cell lines derived 
from hematologic cells (EL4 cells), epithelial breast 
adenocarcinoma (MDA-MB-231 cells) and mesenchymal 
tumors (osteosarcoma K12 cells). We first analyzed CD44 
expression and its ability to bind HA in all tumor cell lines 
to discard a different behavior as a consequence of the loss 
of CD44 expression. Although there are other HA receptors, 
we focused only on the interaction with CD44 because it 
is the main receptor involved in tumor processes [40, 41]. 
In fact, it has been reported that the HA-CD44 interaction 
is associated with the high tumorigenesis of MDA-
MB-231 cells [22]. Several reports have indicated that 
CD44 expression contributes to aggressive progression in 
osteosarcoma [42] as well as in hematologic malignancies 
[43, 44]. Here, the three tumor cell lines evaluated showed 
high levels of CD44 expression, detecting two different 
populations (with low and high expression). Besides, 
the cells bound LMW HA efficiently, and different cell 
populations were observed in each tumor cell line when HA 
binding was analyzed, clearly showing either two or even 
three subpopulations that bound HA with different ability. 
Although the exact biological significance of this finding 
is not fully clear, these differences could partly explain 
the differential behavior found during HA treatments 
in the tumor cell lines evaluated. We will thus continue 
investigating these cell subpopulations to better understand 
the connection with the different responses observed during 
drug treatments in patients, since this might be associated 
with the therapy resistance and/or relapse of cancer disease.
It is well known that drug resistance can arise 
through several mechanisms, including an increase in 
drug efflux via the modulation of cell membrane multidrug 
resistance transporters [6, 45, 46]. It has been demonstrated 
that ECM components, such as HA, modulate drug 
response, affecting the expression and function of different 
drug efflux transporters [47, 48]. 
In the present study, tumor cells were exposed to DOX 
because this compound is widely used as an antineoplastic 
drug for a broad spectrum of tumors [49]. To discard drug 
action over cell viability during the treatments, we used 
different DOX doses (0.5 µM, 1 µM and 2.5 µM), at which 
apoptosis changes were minimal. HA treatment induced a 
decrease in DOX intracellular levels only in T-cell lymphoma 
cells, but this decrease did not impact cell survival as apoptosis 
levels were similar during HA-DOX co-treatment respect to 
the control or DOX treatment alone. As expected, these results 
are a consequence of the modulation of the expression of ABC 
drug transporters involved in DOX efflux, as we observed 
increased ABCB1 mRNA expression. In contrast, our results 
indicated that LMW HA could not play a role as a modulator 
of DOX accumulation in cells derived from solid tumors, 
although these cells have active ABC drug transporters. When 
we analyzed the presence of functional pumps in all cell lines 
by using CsA, an inhibitor of ABC transporters which blocks 
the function of ABCB1 and ABCC1 pumps, we observed 
a reduction of DOX accumulation when the cells were co-
treated with CsA + DOX (data not shown). The results 
suggest that ECM components from hematologic tumors, 
specifically HA, could impact on DOX response, generating 
subpopulations of resistant cells. HA might be involved in 
the conversion of cancer cells into cancer-initiating cells or 
cancer stem cells [10, 24], characterized by high expression of 
ABC transporters and other cancer stem cell markers such as 
CD44 [7].
On the other hand, it has been recently demonstrated 
that mammary tumors show an increased chemoresistance 
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to DOX, which is due not only to a reduction of drug 
internalization, but also to specific interactions with 
the tumor microenvironment. Specifically, it has been 
determined that the “tissue phenotype” or the ECM 
generated around the tumor is responsible for inducing 
survival mechanisms that evade drug response [50]. 
It is well known that the modulation of cell survival 
and proliferation pathways contributes to carcinogenesis 
and drug resistance [11, 39, 51]. Considering these facts, 
we studied the effect of DOX and HA treatment on the 
Wnt/β-catenin and PI3K/Akt pathways. Wnt/β-catenin 
signaling favors pathological angiogenesis by regulating 
the expression of VEGF [52] and interleukin-8 [53]. 
Moreover, in a gastric cancer model, it has been reported 
that, upon DOX chemotherapy, the Wnt pathway is 
activated, promoting tumor invasion and metastasis 
[54]. In the present study, our results indicated that DOX 
treatment in combination with LMW HA enhanced 
β-catenin expression by additive effect, as observed 
in EL4 and MDA-MB-231 cells. HA and DOX alone 
had the ability to modulate the expression of β-catenin, 
whereas the co-treatment with DOX and HA enhanced this 
modulation. However, only the HA-DOX co-treatment 
induced the modulation of β-catenin expression in K12 
cells. As mentioned above, this could be the consequence 
of the differential CD44 expression and HA binding ability 
observed in the different cell lines studied. Nevertheless, 
these findings showed that HA could be involved in DOX 
response, impairing the effect of the drug and favoring 
tumor progression mediated by Wnt/β-catenin signaling. 
We also explored the activation of Akt protein since 
an aberrant activation of this pathway is involved in cancer 
progression and resistance to chemotherapy [55–57]. As 
expected, LMW HA treatment increased p-Akt expression, 
showing that HA could be favoring the activation of this 
pathway in EL4 and MDA-MB-231 cells. However, when 
cells were treated with DOX, these hematologic and 
epithelial tumor cells showed a different behavior. LMW 
HA was able to reverse the anti-tumoral action of DOX 
in EL4 cells, besides the DOX effect was independent of 
the presence of HA. This result allowed us to rule out an 
HA-DOX tumor modulation by this pathway in MDA-
MB-231 cells. p-Akt expression was not detected in K12 
cells in our experimental conditions, although we used an 
antibody that detected all p-Akt isoforms. Thus, we cannot 
elucidate the role of p-Akt in the osteosarcoma cell line in 
association with HA-DOX tumor modulation.
Some studies have shown that cancer cells protect 
ECs from apoptosis after radiation through secretion of 
VEGF and subsequent activation of pro-survival pathways 
[58]. Taking these data into account, we explored an 
unwanted effect observed during chemotherapeutic 
treatment: modulation of angiogenesis. In the tumor 
microenvironment, HA regulates angiogenesis, and 
specifically, LMW molecules have a pro-angiogenic 
action [59, 60]. We hypothesized that LMW HA from 
tumor stroma could also affect the anti-angiogenic action 
of DOX observed in ECs [61, 62]. Published data have 
shown that DOX induces a differential resistance in 
tumor-associated ECs [27, 63]; nevertheless, the potential 
mechanisms involved have not been extensively explored. 
As expected, LMW HA enhanced the angiogenic action of 
the supernatant derived from tumor cells and, surprisingly, 
DOX showed a similar effect. When DOX treatment 
was combined with HA, both EC migration and vessel 
formation in vitro were enhanced. This suggests that 
HA might favor tumor progression and alter a suitable 
response to DOX, enhancing angiogenesis in epithelial 
and mesenchymal derived tumor. Although opposite 
results were observed for hematologic tumor cells in vitro, 
detection of vessel formation in our in vivo model revealed 
that DOX might also affect angiogenesis in the presence 
of HA in lymphoma tumors. This important finding 
confirms that the tumor ECM could reduce the success of 
chemotherapy in different types of tumor.  
Since VEGF is involved in tumor angiogenesis, we 
first explored mechanisms by which HA modulates VEGF 
levels [13]. However, we did not find a significant increase 
in VEGF secretion; in fact, a decrease in this factor was 
observed in K12 cells. These results could be explained by 
two findings. First, VEGF165 exists in different isoforms: 
angiogenic VEGF165a and anti-angiogenic VEGF165b, 
and this proportion could be modulated. For example, 
selective binding of VEGF165a by C-6 OH sulfated HA 
affects VEGF action, enhancing the anti-angiogenic effect 
of VEGF165b [64]. Thus, we can hypothesize that the 
reduction of VEGF in K12 supernatants could be related 
to its anti-angiogenic VEGF function. Second, there are 
other angiogenic factors released by tumor cells, which 
can modulate EC behavior independently of VEGF 
biosynthesis. Thus, in the absence of modulation of VEGF 
expression in EL4 and MDA-MB-231 cells, the observed 
effect could be due to some other potent angiogenic 
molecule. These results could explain that therapies 
focused on the down-regulation of VEGF expression or 
associated cellular signals fail as a consequence of changes 
in the tumor microenvironment and bio-availability of 
other important angiogenic factors [31, 33, 65].
Actually, FGF-1 and FGF-2 have been reported 
to be up-regulated in tumors that relapsed from the 
treatment with an anti-VEGFR antibody [66]. In the 
present study, DOX treatment caused an up-regulation 
of FGF-2 biosynthesis, which might be associated with 
the pro-angiogenic effect observed in combination with 
HA in all the cell lines evaluated. It is well known that 
the mainly fraction of the FGF-2 produced by the tumor 
cells is secreted and remain bind to the heparan sulfate 
proteoglycans in the cytoplasmic membrane. Therefore, it 
could be detected in the cellular lysis extracts instead of 
in the supernatants. This fraction of FGF-2 is the mainly 
isoform detected by ELISA [37]. Besides, we performed 
the ELISA with the supernatants from the tumor cells 
Oncotarget36597www.oncotarget.com
treated with HA + DOX to rule out that the addition of 
HA had affected the interaction between the heparan 
sulfate proteoglycans and FGF-2, and releasing it into the 
cell medium. We found detectable levels of FGF-2 only 
in the ELISA performed from the cell extracts, therefore 
our results could be related to FGF-2 isoforms retain in 
the cytoplasmic membrane in interaction with ECM 
components. In addition to the angiogenic effect of FGF-2, 
certain FGF-2 isoforms that are not secreted from the cell 
and are transported to the nucleus where they regulate cell 
growth or behavior [67, 68]. 
Our results demonstrate for the first time that LMW 
HA is a potential modulator of the angiogenic responses 
by interaction with the chemotherapeutic drug DOX. 
HA in combination with DOX treatment increased EC 
migration and formation of vessel-like structures. These 
results could indicate a different and new mechanism by 
which HA from the tumor ECM could modulate DOX 
response in tumor cells, raising an unwanted effect of this 
drug: promotion of angiogenesis.
MATERIALS AND METHODS
Reagents
Recombinant LMW HA (1–3 × 105 CPN Czech 
Republic) was kindly supplied by Farmatrade (Argentina). 
High glucose Dulbecco’s modified Eagle’s medium (DMEM) 
and DMEM F12 were purchased from MICROVET 
Laboratories (Argentina). TriReagent was from Molecular 
Research Center, Inc (USA). Doxorubicin (DOX) was kindly 
provided by Filaxis Pharmaceuticals S.A (Argentina). Anti-
β-catenin antibody was purchased from Millipore (USA). 
Specific antibody against glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) antibody was from NeoBioLab 
(USA). Anti-phosphorylated Akt (Ser473, Ser472 and 
Ser474) antibody was purchased from R&D System 
(USA) and anti-rabbit secondary horseradish peroxidase 
(HRP) antibody was from Santa Cruz Biotechnology 
(USA). CD44-APC antibody was from BD BioSciences 
(USA) and HA-FITC from Calbiochem (USA). Annexin 
V-FITC apoptosis detection kit was from ImmunoTools 
(Germany). Cyclosporine A was kindly provided by Novartis 
Pharmaceuticals Corporation (Argentina).
Cell lines 
The murine T-cell lymphoma cell line EL4 (TIB-
39™) and MDA-MB-231 human breast cancer cell 
line (HTB-26™) were purchased from ATCC® (USA). 
K12 osteosarcoma cells were provided by Dr. Eugenie 
Kleinerman (University of Texas M.D. Anderson Cancer 
Center, Houston, TX, USA). The HMEC-1 cell line 
was gently provided by Dr. Candal (Centers for Disease 
Control, Atlanta, USA). The MDA-MB-231 human cell 
line was authenticated by Northgene Ltd. Company 
(UK), using highly sensitive DNA testing for Short 
Tandem Repeats The murine cell lines (EL4 and K12) 
were also analyzed to identify each cell line and rule out 
cross contamination with human cell lines by the Quality 
Control Department of the National Institute of Human 
Viral Diseases (INEVH), Argentina. EL4, K12 and 
HMEC-1 cells were maintained in high glucose DMEM 
supplemented with 10% heat-inactivated fetal bovine 
serum (FBS), 2 mM L-glutamine, 100 U/ml streptomycin, 
and 100 mg/ml penicillin, and incubated at 37° C in a 5% 
CO2 atmosphere. Similarly, MDA-MB-231 cells were 
cultured with DMEM F12 supplemented with 10% FBS, 
2 mM L-glutamine, 100 U/ml streptomycin and 100 mg/ml 
penicillin. During all cell cultures, periodic checkups 
of cell morphology as well as strict control of cell line 
passages (5–10th passage) and cell line growth rate were 
performed. In addition, all cell lines were analyzed to 
discard the presence of mycoplasma contamination by 
PCR assay. 
CD44 receptor expression and HA binding 
ability
To determine CD44 expression levels and HA 
binding ability, 5 × 105 cells were incubated with 20 μg/ml 
of HA-FITC or anti-CD44-APC monoclonal antibody in 
100 μl of 1% bovine serum albumin (BSA) in phosphate 
buffered saline (PBS) for 1 h at 4° C and washed twice 
with 1% BSA-PBS. The analysis was performed on FACS 
Canto II flow cytometer (BD Biosciences). Data were 
analyzed using FlowJo software (LLC).
HA and DOX treatments
HA diluted in ultra-pure water and used up to a 
concentration of 6 mg/ml. HA concentrations used in 
the experiments were 20 μg/ml and 100 μg/ml. DOX 
was diluted in sterile saline solution to 40 μM, and used 
in doses of 0.5 μM, 1 μM and 2.5 μM. Cell lines were 
cultured in 12-well plates for 24 h before treatment. The 
next day, all supernatants were removed and fresh culture 
medium without FBS was added to each well. After that, 
LMW HA was added to the medium for 24 h, and after 
12 h of this treatment, DOX was added for the remaining 
12 h of HA treatment. Subsequently, supernatants were 
collected and conserved at −80° C until their use.
DOX accumulation assay 
Since DOX has an emission spectrum detectable 
by flow cytometry between 550–600 λ, DOX efflux was 
analyzed measuring intracellular drug accumulation as 
previously described [11]. Cells (5 × 105) were treated as 
mentioned above and DOX fluorescence was collected 
through a 564–606 nm band-pass filter. To study the 
presence of functional drug efflux pumps in all cell lines, 
Oncotarget36598www.oncotarget.com
we also studied DOX accumulation in the presence or 
absence of 100 µM of the inhibitor CsA. Samples were 
analyzed using FACS Canto II Flow cytometer and data 
were evaluated using FlowJo software.
Apoptosis detection assay
To evaluate apoptosis levels induced by DOX 
treatments, the Annexin V-FITC apoptosis detection kit 
(ImmunoTools) was used, following the manufacturer´s 
protocol. Samples were analyzed using FACS Canto II Flow 
cytometer and data were evaluated using FlowJo software. 
RT-qPCR 
After each treatment with DOX and HA in EL4 
and MDA-MB-231 cells, total RNA was extracted by 
Tri Reagent (Sigma-Aldrich Co). RNA integrity and 
quantification were assessed by spectrophotometry, 
measuring OD260 in a Picodrop® instrument. Two 
micrograms of RNA were reverse-transcribed with 
200 U of RT M-MLV Reverse Transcriptase (Promega) 
and 2.5 pmol/µl of Oligo (dT) primers (GenBiotech). 
cDNAs were then subjected to real-time quantitative 
PCR (RT-qPCR) using FastStart SYBR Green Master 
(Roche) and 200 nM of each specific primer (Invitrogen): 
murine ABCB1 forward 5′-CTG GTT TGA TGT GCA 
TGA CG-3′ and reverse 5′-GAA CAT TCC GAT TTT 
GTC ACC-3′; murine ABCG2 forward 5′-TCG CAG 
AAG GAG ATG TGT TG-3′ and reverse 5′-TGG GTC 
CCA GAA TAG CAT TAA G-3′; human FGF-2 forward 
5′-CCTGGCTATGAAGGAAGATGG 3′ and reverse 
5′ TCGTTTCAGTGCCACATACC 3′ and human EGF 
forward 5′ TGA TAA GCG GCT GTT TTG G-3′ and 
reverse 5′-CAC CAA AAA GGG ACA TTG C-3′. PCR 
conditions were 90 seconds at 94° C and then 40 cycles of 
30 seconds at 94° C, 30 seconds at 60° C and 30 seconds 
at 72° C. Values were normalized to levels of murine 
and human glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH; used as housekeeping) transcript (forward 5′-
GGG GCT GCC CAG AAC ATC AT-3′ and reverse 5′-
GCC TGC TTC ACC ACC TTC TTG-3′). A non-template 
control was run in every assay and all determinations were 
performed in duplicate in three separate experiments.
Protein extracts and western blot analysis
To analyze β-catenin and p-Akt expression, tumor 
cell lines were treated with HA and DOX (1 × 106) as 
described above and then lysed with lysis buffer for 
30 minutes at 4° C [69]. After centrifugation of cells, 
supernatants were preserved, and protein concentration 
was measured using Bradford protein assay. Protein 
extracts were stored at −80° C until use. Equal 
amounts of protein were resolved by 0.1% SDS-10% 
polyacrylamide gel denaturing electrophoresis (SDS-
PAGE) and transferred onto a nitrocellulose membrane. 
The membranes were incubated with a specific anti-
β-catenin or p-Akt antibody and GAPDH overnight at 
4° C, and then incubated with horseradish peroxidase-
labeled secondary antibody for 1.5 h at room temperature. 
Finally, HRP chemiluminescence reaction was detected 
using a stable peroxide solution and an enhanced luminol 
solution. Images were obtained with an ImageQuant 4000 
mini bioluminescent image analyzer (GE HealthCare 
LifeSciences) and analyzed using ImageJ 1.50 b software 
package (National Institutes of Health, USA).
Endothelial cell wound healing assay
HMEC-1 micro-endothelial cells were grown to 
confluence on 24-well plates. Then, 18 hours before starting 
the assay, HMEC-1 cells were subjected to FBS starvation 
to avoid proliferation effects. Consistently shaped wounds 
were made using a sterile 100-µl pipette tip across each well, 
creating a cell-free area line [70]. At that point, cells were 
exposed to the supernatants of EL4, K12 or MDA-MB-231 
cells (previously treated with LMW HA, DOX, or LMW 
HA + DOX) diluted at 1:1 ratio with DMEM. For negative 
control, cells were exposed to DMEM without FBS. 
Controls to discard residual effects of DOX or HA on ECs 
were also performed. Three images were captured in the 
same coordinates point at 0, 4, 8 and 22 h after performing 
the wound. The gap size of the wound was measured and 
analyzed using ImageJ 1.50b software package.
Endothelial cell tube formation assay
A tube formation assay was performed using 
Geltrex™ LDEV-Free reduced growth factor basement 
membrane matrix (GibcoTM Life Technologies) [71]. To 
this end, 40 μl of Geltrex™/well was seeded in a 96-well 
plate and allowed to polymerize for 30 minutes at 37° C. 
HMEC-1 cells (2 × 104), FBS-starved 18 h before, were 
loaded into GELTREX and exposed to the supernatants 
of EL4, K12 and MDA-MB-231 cells from the different 
treatments. For positive control, 100 ng/ml of recombinant 
human VEGF was used to stimulate tube formation of 
HMEC-1 cells, whereas for negative control, only DMEM 
medium was used. After 6 h of incubation at 37° C, cells 
were stained using eosin solution. Quantification was 
performed by analyzing the cell-free area from five images 
per well with the ImageJ 1.50 b software package. 
VEGF and FGF-2 ELISAs
Human and mouse VEGF secretion levels were 
determined by the DuoSet ELISA Kit (R&D System, 
USA) from free-cell culture supernatants after treating 
cell lines with DOX and HA. FGF-2 expression levels 
were determined by the DuoSet ELISA Kit (R&D System, 
USA) from protein extracts of all cell lines treated with 
DOX and HA. The assays were carried out according to 
the instructions provided by the manufacturer. 
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In vivo experiments
EL4 cells were s.c. injected, at a dose of 
1 × 106 cells/animal, into the right flank of four-to six-
week-old C57BL/6 mice. Tumors were allowed to reach 
approximately 85 mm3 in size before DOX and HA 
treatments were started. Animals were distributed in 
different groups, and then s.c. treated on day 7 after tumor 
inoculation with saline, 20 μg/ml or 100 μg/ml of LMW 
HA, 1 μM of DOX, 1 μM of DOX plus 20 μg/ml of LMW 
HA or 1 μM of DOX plus 100 μg/ml of LMW HA. After 
2 days, on day 9, mice were sacrificed, and tumors were 
removed, fixed in 4% formalin and embedded in paraffin. 
Before staining, 3-μm sections were deparaffinized 
and dehydrated. Slides were rinsed with PBS and 
dyed with DAPI 0.3 µg/ml plus fluorescein-labeled 
Griffonia (Bandeiraea) Simplicifolia Lectin I 20 µg/ml 
(GSL I, Vector Laboratories # FL-1101), which binds 
specifically to ECs in mouse tissues [72]. Furthermore, 
sections for histological analysis were routinely stained 
with hematoxylin/eosin. The sections were rinsed with 
PBS and then mounted on microscope slides. Micrographs 
of the stained sections were taken with a Nikon Eclipse 
E800 fluorescence microscope. Images were analyzed 
with the ImageJ 1.50b software package. 
Statistical analysis
For statistical analysis, 95% confidence intervals 
(CI) were determined by calculating arithmetic mean 
values and variance (standard deviation, SD) of three 
independent experiments. To evaluate whether differences 
between the values obtained were significant, the 
T Student’s test (T-test, Mann–Whitney) was used in 
the case of comparisons between two groups. Analysis 
of variance (ANOVA, Tukey Test) was also used to 
evaluate the differences between values of more than two 
experimental groups. The software Prism (GraphPad, San 
Diego, CA, USA) was used, considering a p value < 0.05 
as statistically significant.
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